Law & Ethics
Legal considerations, ethical frameworks, and responsible approaches to education and community.
16 articles available
Start Here
U.S. Legislation Map
Explore the evolving legal landscape with our interactive state-by-state guide.
5 minDC Legal Guide
Neutral guide to D.C. psychedelic and cannabis policy, enforcement limits, and federal law.
15 minIndigenous & Traditional Use
Sacred traditions, cultural appropriation, and ethical considerations.
14 minRelated Journal Articles
Field Notes #6: Dispatches from D.C. as Three Psychedelics Land at FDA
Field Notes are timely, candid voice notes from our Founder and Editor, Josh Hardman, that give our Pα+ readers a pulse on recent developments in psychedelic drug development, policy, and access.
Robert Rush: Emergency Scheduling, 7-OH, and the War on Research
Attorney Robert Rush joins Joe in Breckenridge to talk about challenging DEA scheduling decisions, from the 2024 DOI and DOC hearing to the emergency scheduling of 7-OH compounds and SR-17018.
The Problems We Will Be Lucky to Have
In November 2020, Oregon voters passed the first ballot measure in the country to create a legal, supervised psilocybin program, Measure 109.
Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
Nonprofit psychedelic research organisation Usona Institute has completed its submission of a new drug application (NDA) to the U.S.
FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending
This morning, NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for its preservative-free ketamine produ...
Oregon U-turns on Doubling Psilocybin License Fees
Oregon’s health regulators shelved a proposal that would have doubled what psilocybin businesses and facilitators pay for their state licenses.
From Ecstasy Rising to Peaking: Jordan Kronick on 20 Years Covering Psychedelics
Documentary filmmaker Jordan Kronick joins Joe to discuss Peaking: Psychedelics and the Pursuit of Happiness, a new psychedelic documentary that takes cameras into the dosing room across six psychedel...
Weekly Psychedelic Policy Briefing: October 12, 2026
FDA laid out how the first federally funded ibogaine trials could be run, with inpatient cardiac monitoring and a 10 mg/kg starting dose ceiling.
Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
Kenneth Tupper joins Joe Moore for a wide-ranging conversation on harm reduction, drug education, British Columbia’s toxic drug crisis, ayahuasca policy, entheogenic education, and what psychedelic pu...
2026 Third Quarter — Legislative Wrap Up
Since the beginning of 2026, at least 23 states have introduced psychedelic legislation, signaling continued momentum and openness in how local and federal leaders address mental health, substance use...
MAPS and International Alliance of Psychedelic Therapy Practitioners Announce Partnership to Advance Training for Psychedelic-Assisted Therapy
Collaboration will increase access to practitioner education in the United States and internationally.
Quarterly Psychedelics Briefing: Q3 2026
Welcome to our Q3 2026 Quarterly Briefing. Every three months, our Founder & Editor Josh Hardman walks you through major developments from the prior quarter across drug development, policy and reg...
Statement on DEA attempt to reschedule five tryptamines
Last week, the DEA moved to place five little-known psychedelic compounds — 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT — into Schedule I of the Controlled Substances Act.
By continuing to use this site, you agree to our Terms and Privacy Policy.

